Operational Excellence

Our Innervation platform tracks patients throughout the course of their treatment. It gives pharmaceutical/biotechnology companies, specialty pharmacies, and physicians access to information and opportunities that simply don't exist anywhere else.

Benefits for Pharma/Biotech Clients Benefits for Pharma/Biotech Clients

Take control of your distribution channel. Understand the reasons behind non-starts and discontinues. See changes in script written within a day of when they happen.

Benefits for Specialty Pharmacies Benefits for Specialty Pharmacies

Your physicians get real-time patient status updates and are invited to participate in clinical studies. Pay for service means you’re compensated for time spent advocating for patients.

Benefits for Payers Benefits for Payers

Real-time patient status makes the PA process completely transparent. You’re increasing the efficiency of the approval process and getting access to real-time outcomes data.

Our mission is to improve the quality of care in patient outcomes through the coordinated efforts of all patient care stakeholders.

Real-Time Data / Real-World Patients

Conducting clinical trials through the Innervation platform, Trio was the first to publish real-world outcomes for new HCV regimens. Innervation has collected longitudinal data on thousands of patients. See our full list of citations.

Our Management Team

Brent Clough

Chief Executive Officer
Brent Clough co-founded Trio Health in 2013. Prior to this, Brent founded IntrinsiQ Financial in 2004, which merged with IntrinsiQ Research in 2006. IntrinsiQ is the leader for oncology clinical software that tracks and manages complex chemotherapy workflows. IntrinsiQ developed the largest longitudinal patient database that has been widely adopted by the pharmaceutical companies. Upon the merger, Brent was elected President and CEO of the company. The company grew from a start-up to 90 employees prior to being acquired by Amerisource Bergen.

Before entering the healthcare industry, Brent spent eight years as a Vice President at Goldman Sachs (1996-2004) working in the investment research and equities division. Prior to Goldman, Brent worked at First Call Corporation (1988-1996) within the institutional sales and broker dealer division.

Yoori Lee

Yoori co-founded Trio Health. Yoori spent over 15 years at Leerink Swann LLC, a leading healthcare investment bank where she was Managing Director, and Director of MEDACorp Services. Yoori helped found the MEDACorp network since inception. Her cadre of experts included more than 35,000 healthcare professionals including, but not exclusive to, clinical medicine, biomedical research, regulatory affairs, public policy, healthcare administration and healthcare information technology.

Yoori has delivered value-driving business and decision support strategies to companies ranging from emerging growth to the world’s largest pharmaceutical companies. With nearly twenty years of consulting experience, Yoori has unique experience in scientific, clinical, regulatory and commercial solutions for clients by bringing together a best in class network of in-the-trenches consultants into the strategic process. Through these close relationships and collaborations, she has helped to develop intricate consulting strategies, amassed numerous advisory boards, and aligned strategic objectives based upon thorough assessments of competitive landscapes as well as developing and managing pre and post marketing programs.

Scott Milligan, Ph.D.

Healthcare Analytics
Scott leads Analytics for Trio Health. His expertise is in providing data-centric products and solutions to payers, providers, pharmacies, specialty drug manufacturers and institutional investors. Prior to joining Trio Health, Scott served as Director of Clinical Analytics for Cardinal Health Specialty Solutions where he provided analytics in support of disease and drug brand management. At IntrinsiQ Research, an AmerisourceBergan company, he served as Vice President of Analytics and was responsible for guiding consultative projects. At Morpace Pharma, he directed the Oncology Group in predictive analytics.

Scott received his B.S. from Butler University, his Ph.D. from the University of Notre Dame and completed his post-doctoral research in the Department of Pediatric Oncology at the Dana-Farber Cancer Institute and Harvard Medical School.

Contact Us

Phone & Email


La Jolla

1020 Prospect Street, Suite 312
La Jolla, CA 92037


7 Wells Avenue, Suite 27
Newton, MA 02459